Neuroendocrine Tumor Clinical Trials

Find Neuroendocrine Tumor Clinical Trials Near You

CLINical, Pathological and outcomE compArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors: a Retrospective Observational Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 \> 20%). The objective of this retrospective single-centre translational study will be to explore whether patients differ clinically in terms of diagnosis and treatment management. Currently, well differentiated high grade pulmonary NETs are managed using extrapolated algorithms from duodeno-pancreatic NETs, underlining a significant unmet clinical need. This is likely due to the rarity, uncertain pathological and molecular classification, and heterogeneous clinical course of well differentiated high grade pulmonary NETs. In this study a retrospective data-base of pulmonary, thymic and duodeno-pancreatic NETs with Ki-67 \> 20% will be created in order to analyze diagnostic and therapeutic pathways, clinical outcomes, imaging, disease evolution and molecular profiling. This study will adopt a hypothesis-generating approach to explore whether patients in these distinct groups differ clinically in terms of diagnosis and treatment management.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Histologically confirmed diagnosis of well-differentiated high grade neuroendocrine tumor (Ki-67 \> 20% according to WHO 2022) performed or reviewed by a NEN-dedicated pathologist.

• Primary tumor site:thyme, lung and duodenum-pancreas NETs.

• Advanced stage of tumor disease and Any number of lines of therapy

• Sufficient available clinical data on diagnosis, treatments, outcomes.

Locations
Other Locations
Italy
European Institute of Oncology
RECRUITING
Milan
Contact Information
Primary
Cristiana Mulargiu, MD
divisione.gastrointestinale@ieo.it
00390257489258
Backup
Francesca Spada, MD
divisione.gastrointestinale@ieo.it
00390257489258
Time Frame
Start Date: 2026-01-01
Estimated Completion Date: 2026-03-31
Participants
Target number of participants: 34
Treatments
thymic and pulmonary neuroendocrine neoplasms
thymic and pulmonary well differentiated high grade Advanced stage neuroendocrine tumor
gastroenteropancreatic neuroendocrine neoplasms
gastroenteropancreatic well differentiated high grade neuroendocrine Advanced stage neuroendocrine tumor
Sponsors
Leads: European Institute of Oncology

This content was sourced from clinicaltrials.gov

Similar Clinical Trials